REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo shows promise against Hard-to-Treat leukemia
Disease control OngoingThis study tests whether combining two targeted drugs, venetoclax and ibrutinib, can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It includes 234 patients whose cancer has returned or is hard to treat, as well as some untreated high-risk …
Matched conditions: REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control OngoingThis early-stage trial tests a new drug called BGB-21447 in about 112 people whose B-cell blood cancers (like lymphoma or leukemia) have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also…
Matched conditions: REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
Could taking drug breaks tame leukemia side effects?
Disease control OngoingThis study tests whether giving duvelisib on an irregular schedule can control chronic lymphocytic leukemia or small lymphocytic lymphoma as well as standard dosing, but with fewer severe side effects. Fifteen adults with cancer that returned or didn't respond to prior treatment …
Matched conditions: REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…
Matched conditions: REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Double-targeted cell therapy takes on hard-to-treat blood cancers
Disease control OngoingThis early-phase trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to recogniz…
Matched conditions: REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New cocktail targets tough leukemia cases
Disease control OngoingThis early-phase study tests a combination of three drugs (lenalidomide, ibrutinib, and rituximab) in 12 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatment. The main goal is to find the safest d…
Matched conditions: REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC